مشخصات مقاله | |
ترجمه عنوان مقاله | Oocytes سلول های بنیادی |
عنوان انگلیسی مقاله | Oocytes from stem cells |
انتشار | مقاله سال 2018 |
تعداد صفحات مقاله انگلیسی | 20 صفحه |
هزینه | دانلود مقاله انگلیسی رایگان میباشد. |
پایگاه داده | نشریه الزویر |
نوع نگارش مقاله |
مقاله مروری (review article) |
مقاله بیس | این مقاله بیس نمیباشد |
نمایه (index) | scopus – JCR – MedLine |
نوع مقاله | ISI |
فرمت مقاله انگلیسی | |
ایمپکت فاکتور(IF) |
2.710 در سال 2017 |
شاخص H_index | 70 در سال 2018 |
شاخص SJR | 1.243 در سال 2018 |
رشته های مرتبط | زیست شناسی، پزشکی |
گرایش های مرتبط | علوم سلولی و مولکولی، خون و آنکولوژی |
نوع ارائه مقاله |
ژورنال |
مجله / کنفرانس | بهترین روش ها و تحقیقات مامایی و زنان و زایمان بالینی – Best Practice & Research Clinical Obstetrics & Gynaecology |
دانشگاه | Department of Anatomy and Developmental Biology – Monash University – Australia |
کلمات کلیدی | Oocytes، فولیکول زایی، باروری، سلول های بنیادی، سرطان، شیمی درمانی |
کلمات کلیدی انگلیسی | Oocytes, folliculogenesis, fertility, stem cells, cancer, chemotherapy |
شناسه دیجیتال – doi |
https://doi.org/10.1016/j.bpobgyn.2018.07.006 |
کد محصول | E9778 |
وضعیت ترجمه مقاله | ترجمه آماده این مقاله موجود نمیباشد. میتوانید از طریق دکمه پایین سفارش دهید. |
دانلود رایگان مقاله | دانلود رایگان مقاله انگلیسی |
سفارش ترجمه این مقاله | سفارش ترجمه این مقاله |
فهرست مطالب مقاله: |
Highlights Abstract Keywords Overview of folliculogenesis and building a competent oocyte Cancer treatments compromise folliculogenesis and the ability to build a competent oocyte Current fertility preservation options The potential application of stem cells to fertility preservation Practical issues in research and ethics Summary Conflict of interest Acknowledgments Appendix A. Supplementary data Research Data References |
بخشی از متن مقاله: |
Abstract
Folliculogenesis describes the process of activating an oocyte-containing primordial follicle from the ovarian reserve, and its development to the mature ovulatory stage. This process is highly complex and is controlled by extra- and intra-ovarian signalling events. Oocyte competence and capacity for fertilisation to support a viable pregnancy is acquired during folliculogenesis. Cancer, and cancer-based therapies can negatively affect this process, compromising fertility. Currently, preservation of fertility in these patients remains limited to surrogacy, oocyte freezing, oocyte donation or in vitro maturation (IVM). Recent reports of stem cells being used to produce fully competent oocytes, and subsequently healthy offspring in mice, has opened up a novel avenue for fertility preservation. However, translating these findings into human health first relies on enhancing our understanding of follicle growth, and mimicking its intricacies in vitro. Indeed, the future of oocytes from stem cells in humans comes with many possibilities, but currently faces several technical and ethical obstacles. Overview of folliculogenesis and building a competent oocyte The ovarian follicle containing an oocyte surrounded by somatic cells is the niche for the female germline which must be nourished and protected from sustained damage. The germ cells that eventually form follicles are first identified at 4 weeks gestation among stem cells in the embryonic epiblast. After migration to the gonadal ridge and proliferation, they enter meiosis and form nests surrounded by pre-granulosa cells. The nests breakdown between 25 and 40 weeks gestation to form primordial follicles, each of which contains an oocyte arrested in prophase of the meiotic cell cycle, surrounded by a single layer of squamous or flattened pre-granulosa cells. This process called oogenesis occurs over 150 and 250 days in the fetal ovary (Figure 1) (1, 2). At birth, the human female has approximately 300,000 primordial follicles (range 35,000-2.5 million), defined as the ovarian reserve (1, 3).This reserve is not replenished after birth under normal physiological circumstances. The size of the ovarian reserve declines with age until <1000 primordial follicles are present at the time of menopause (3, 4). The length of the fertile period from puberty to menopause is determined by (a) the rate of death of primordial follicles before being selected to activate, (b) their rate of activation, and (c) the size of the ovarian reserve at birth (1, 5). It follows that genetic or environmental factors such as chemotherapeutic agents or radiation that reduce the size of the ovarian reserve will shorten or even eliminate the fertile period. |